F10 and thrombophilia: There are four clinically approved direct FXa inhibitors, including rivaroxaban, apixaban, edoxaban as well as betrixaban) and one indirect FXa inhibitor fondaparinux for use as anti-thrombotic agents in patients with hypercoagulable states65.